Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up - Still a Buy?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $10.75, but opened at $11.00. Theravance Biopharma shares last traded at $10.80, with a volume of 17,795 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Jones Trading assumed coverage on Theravance Biopharma in a research report on Tuesday. They set a "buy" rating and a $24.00 price target for the company. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, Theravance Biopharma presently has a consensus rating of "Moderate Buy" and an average price target of $14.50.

Theravance Biopharma Trading Up 0.0%

The business has a 50 day simple moving average of $9.61 and a two-hundred day simple moving average of $9.45. The stock has a market cap of $537.76 million, a price-to-earnings ratio of -10.65 and a beta of -0.09.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The firm had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. Research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the completion of the sale, the senior vice president now directly owns 336,918 shares in the company, valued at approximately $3,706,098. This trade represents a 6.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of Theravance Biopharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock valued at $8,121,000 after acquiring an additional 4,823 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Theravance Biopharma by 16.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company's stock valued at $610,000 after buying an additional 9,315 shares during the period. ProShare Advisors LLC acquired a new stake in shares of Theravance Biopharma in the 4th quarter valued at approximately $119,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Theravance Biopharma by 27.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company's stock worth $1,412,000 after buying an additional 32,534 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of Theravance Biopharma by 50.4% in the 4th quarter. Deutsche Bank AG now owns 46,550 shares of the biopharmaceutical company's stock worth $438,000 after purchasing an additional 15,608 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.